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An ADHERE (Acute Decompensated
Heart Failure National Registry) Analysis
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Robert Jessie, MD, FACC,§ Gregg C. Fonarow, MD, FACC,¶ Janet Wynne, MS,
Roger M. Mills, MD, FACC
San Diego, Los Angeles, and Mountain View, California; Cleveland, Ohio; and Richmond, Virginia
Objectives We undertook this analysis to determine whether there is a relationship between the time to measurement of
immunoreactive B-type natriuretic peptide (iBNP) and early intervention for acutely decompensated heart failure
(ADHF) and whether these variables are associated with morbidity and mortality in ADHF patients.
Background Although natriuretic peptides (NPs) can aid emergency department (ED) physicians in the diagnosis of ADHF, the
relationship between the time to measurement of NP levels and time to treatment is not clear. In addition, the
impact of time to treatment on clinical outcomes has not been demonstrated.
Methods Patients from ADHERE (Acute Decompensated Heart Failure National Registry) who were admitted to the ED
and who received intravenous diuretics were included. Recordings of iBNP levels and the timing of intravenous
diuretic therapy were documented. Patients were divided by quartiles of time to treatment and iBNP levels, cre-
ating 16 categories.
Results In 58,465 ADHF episodes from 209 hospitals, patients with the longest average time to iBNP draw also had the
longest time to treatment. Mean ED time increased with increased time-to-treatment quartiles. Rales on initial
examination were associated with early recognition of HF and earlier institution of therapy. The later the treat-
ment took place, the fewer patients were asymptomatic at the time of hospital discharge. Within the time-to-
treatment quartiles, mortality increased with increasing iBNP. Treatment delay was independently, but modestly,
associated with increased in-hospital mortality with a risk-adjusted odds ratio 1.021, 95% confidence interval
1.010 to 1.033, and p  0.0001, per every 4-h delay.
Conclusions In the ED setting, delayed measurement of iBNP levels and delay in treatment for ADHF were strongly associ-
ated. These delays were linked with modestly increased in-hospital mortality, independent of other prognostic
variables. The adverse impact of delay was most notable in patients with greater iBNP levels (Registry for Acute
Decompensated Heart Failure Patients; NCT00366639). (J Am Coll Cardiol 2008;52:534–40) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.010h
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ucute decompensated heart failure (ADHF) occurs fre-
uently, accounting for more than 1 million hospitalizations
nnually in the U.S. (1). Prompt and accurate diagnosis of
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ccepted May 12, 2008.eart failure (HF) in the emergency department (ED) is a
ecessary first step for insuring that early and appropriate
herapy is given. Previous work has suggested that delayed
herapy may be associated with increased length of stay and
ortality (2–4). A better understanding of the complex
rocess of timely diagnosis and treatment may help to
mprove patient care.
A substantial body of prospective, randomized trial data
as demonstrated that laboratory testing for immunoreac-
ive B-type natriuretic peptide (iBNP) levels represents a
seful and cost-effective adjunct for the diagnosis of HF in
he undifferentiated patient presenting with shortness of
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August 12, 2008:534–40 BNP and Treatment Timereath (5). Even when a high pretest likelihood of heart
ailure based on the clinical presentation is present, the
easurement of iBNP gives added important prognostic
nformation that might help drive triage and treatment
ecisions.
Although natriuretic peptide (NP) (i.e., B-type natri-
retic peptide [BNP] and N-terminal pro-B-type natri-
retic peptide) levels clearly aid in the ED diagnosis of HF
5,6), it is unknown whether there is a relationship between
he time to NP levels and initiation of treatment in patients
ith suspected ADHF. Furthermore, it is unknown
hether the timing of obtaining NP levels influences
linical outcomes in this setting. The purpose of this
nalysis is to determine whether there is a relationship
etween the time to measurement of iBNP and time to
nitial treatment and whether these variables are associated
ith morbidity and mortality among patients presenting
ith ADHF.
ethods
his analysis was performed with ADHERE (Acute De-
ompensated Heart Failure National Registry). This regis-
ry collected detailed patient hospitalization data from
nitial presentation in the hospital or ED until discharge,
ransfer, or in-hospital death (7,8). The registry contains
ata on patients hospitalized with acute decompensated HF
n community, tertiary, and academic centers from all
egions of the country (8). For the purpose of the registry,
DHF was defined as new-onset decompensated HF or
ecompensation of chronic, established HF with symptoms
ufficient to warrant hospitalization. The design, methods,
nd patient characteristics in the ADHERE registry have
een described previously (7).
In brief, medical records were reviewed at participating study
ites, and data from consecutive eligible male and female
atients 18 years of age at the time of hospitalization were
ntered in the registry with an electronic case report form
ncorporating real-time validity checking (7,8). These data
ncluded demographic information, medical history, baseline
linical characteristics, initial evaluation, treatment received,
rocedures performed, hospital course, and patient disposition.
tandardized definitions were used for all patient-related vari-
bles, clinical diagnoses, and hospital outcomes.
Importantly, registry participation did not require any
lteration of treatment or hospital care, and entry of data
nto the registry was not contingent on the use of any
articular therapeutic agent or treatment. Institutional re-
iew board approval was required for all participating
enters; however, informed consent of individuals was not
equired for registry entry. To preserve patient confidenti-
lity, direct patient identifiers were not collected, and data
re reported only in aggregate format. Therefore, registry
ntries reflect individual hospitalization episodes, not indi-
idual patients, and multiple hospitalizations of the same
atient occur as separate records. tIn the beginning of 2003, the
DHERE registry hospitals be-
an to use expanded range BNP
esting (range 0 to 5,000 pg/ml).
n this current study, we analyzed
he ADHERE registry data from
pril 2003 through May 2006.
here were 187,575 records en-
ered in the ADHERE registry
rom inception, and 95,898 (51%)
atient episodes had iBNP levels
btained. There were 37,433
ecords that were excluded from
his analysis because ED was not
he initial point of care, the records
ere missing time to intravenous
iuretics or time to iBNP being
rawn, or the hospitalization oc-
urred before the extended range
BNP assay was widely available. Data from 209 sites were used
or this analysis.
tudy population. For this analysis, only patients admitted
o the emergency department, receiving intravenous (IV)
iuretics and having an iBNP level recorded were included.
nclusion criteria also required that the timing of IV diuretic
herapy was documented. Previous ADHERE registry analy-
es have shown that parenteral loop-blocking diuretics are the
rst pharmacologic intervention in ADHF treatment in more
han 90% of patients treated for ADHF. Time to treatment
as defined as the time from ED admission to first use of IV
iuretic. Time to treatment and iBNP levels being drawn were
ivided into quartiles, creating 16 possible patient subgroups.
tatistical analyses. By using univariate analysis, we com-
ared demographic, therapeutic, and outcome variables
cross quartiles of time-to-treatment administration for the
otal population and within each iBNP quartile. The hy-
othesis of no differences in patients’ characteristics and
utcomes was tested with the chi-square, analysis of vari-
nce, and Kruskal-Wallis tests, as appropriate. Kruskal-
allis testing was used to analyze outcome variables with
kewed distribution. Two-sided p values were reported. A
otal of 1.2% of records were excluded for 1 or more missing
alues. With the large sample size, statistical significance
ith small differences in clinical variables was expected.
Multivariable modeling was performed for time to
NP and time to IV diuretics in relation to in-hospital
ortality risk. The models included variables previously
emonstrated to have the greatest prognostic value in the
DHERE registry (8). The adjusted model includes
ovariates for age, blood urea nitrogen, systolic blood
ressure, diastolic blood pressure, creatinine, sodium,
eart rate, and dyspnea at rest. Generalized estimating
quations (GEE) models were used to adjust for the
orrelation of data within hospitals. An additional model
as developed to determine hospital and patient charac-
Abbreviations
and Acronyms
ADHERE  Acute
Decompensated Heart
Failure National Registry
ADHF  acute
decompensated heart
failure
CI  confidence interval
ED  emergency
department
GEE  generalized
estimating equation
HF  heart failure
iBNP  immunoreactive
B-type natriuretic peptide
ICU  intensive care uniteristics that were predictive of time to BNP levels of 2 or
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BNP and Treatment Time August 12, 2008:534–40ore hours. All variables that were univariate predictors
or this outcome were entered into the model. Both
orward and backward selection yielded similar variables.
hese analyses were performed using version 8.2 of SAS
oftware (SAS Institute, Cary, North Carolina).
esults
here were 187,575 records entered in the ADHERE
egistry from inception. During this time 95,898 (51%)
haracteristics of Patient Cohorts Divided by Time to Treatment W
Table 1 Characteristics of Patient Cohorts Divided by Time to
Characteristic
Q1
<1.05
(n  14,785)
Q2
1.05–2.27
(n  14,475)
Age, Q1 [median] Q3 65.3 [76.1] 83.6 65.2 [76.5] 84.0
Gender (male), n/total (%) 6,967/14,780 6,848/14,473
(47.1) (47.3)
Black race, n/total (%) 2,631/14,277 2,711/13,941
(18.4) (19.4)
White race, n/total (%) 10,918/14,277 10,470/13,941
(76.5) (75.1)
Past medical history
Atrial fibrillation, n/total (%) 4,383/14,785 4,627/14,475
(29.6) (32.0)
Coronary artery disease, n/total (%) 9,076/14,785 8,499/14,475
(61.4) (58.7)
Renal insufficiency, n/total (%) 4,500/14,785 4,151/14,475
(30.4) (28.7)
Dialysis, n/total (%) 476/14,785 309/14,474
(3.2) (2.1)
Current smoker, n/total (%) 2,042/13,776 1,969/13,481
(14.8) (14.6)
HF history, n/total (%) 11,528/14,785 11,028/14,475
(78.0) (76.2)
Initial evaluation
Edema, n/total (%) 10,000/14,785 9,860/14,475
(67.6) (68.1)
Rales, n/total (%) 11,726/14,785 10,656/14,475
(79.3) (73.6)
First chest X-ray with congestion,
n/total (%)
12,144/14,417 11,075/14,062
(84.2) (78.8)
BUN (mg/dl), Q1 [median] Q3 18.0 [25.0] 38.0 18.0 [25.0] 38.0
Creatinine (mg/dl), Q1 [median] Q3 1.0 [1.3] 1.8 1.0 [1.3] 1.8
Systolic blood pressure (mm Hg),
Q1 [median] Q3
129.0 [150.0] 177.0 123.0 [144.0] 166.
iBNP level (pg/ml), Q1 [median] Q3 455.1 [848.0] 1,661.0 467.0 [887.0] 1,73
Time to iBNP level (h), Q1 [median] Q3 0.3 [0.6] 1.0 0.5 [0.8] 1.4
Mean (SD) 2.9 (12.4) 2.7 (11.3)
Hospitalization
Time in ED (h), Q1 [median] Q3 2.8 [4.0] 5.8 3.5 [4.8] 6.5
Vasoactive treatment, n/total (%) 5,699/14,785 3,994/14,475
(38.5) (27.6)
Hospital length of stay, Q1 [median] Q3 2.6 [4.0] 6.7 2.6 [3.9] 6.4
ICU length of stay, Q1 [median] Q3 1.2 [2.2] 3.9 1.2 [2.3] 4.0
Mortality, n/total (%) 535/14,785 470/14,475
(3.6) (3.2)values for continuous variables are from a *1-way analysis of variance, a †chi-square for categorical va
BUN  blood urea nitrogen; ED  emergency department; HF  heart failure; iBNP  immunoreactiveatient episodes had iBNP levels obtained. An additional
7,433 records were excluded from this analysis because ED
as not the initial point of care, the records were missing
ime to intravenous diuretics or time to iBNP, or the
ospitalization occurred before the extended range iBNP
ssay was widely available (before April 2003). This study
ncluded 58,465 ADHF episodes from 209 hospitals.
Table 1 shows the patients’ demographic, clinical, and
aboratory variables by quartile of door-to-treatment time.
travenous Diuretics
ment With Intravenous Diuretics
rtile of Time to Diuretic Treatment
Q3
2.28–4.98
(n  14,560)
Q4
>4.98
(n  14,645)
All
(n  58,465) p Value
65.5 [77.1] 84.3 65.1 [76.5] 83.8 65.3 [76.5] 83.9 0.0033*
6,738/14,558 6,896/14,641 27,449/58,452 0.2943†
(46.3) (47.1) (47.0)
2,692/14,032 2,883/14,152 10,917/56,402 0.0005†
(19.2) (20.4) (19.4)
10,492/14,032 10,444/14,152 42,324/56,402 0.0001†
(74.8) (73.8) (75.0)
4,752/14,560 4,743/14,645 18,505/58,465 0.0001†
(32.6) (32.4) (31.7)
8,345/14,560 8,414/14,645 34,334/58,465 0.0001†
(57.3) (57.5) (58.7)
4,006/14,560 4,234/14,645 16,891/58,465 0.0001†
(27.5) (28.9) (28.9)
309/14,560 310/14,645 1404/58,464 0.0001†
(2.1) (2.1) (2.4)
1,861/13,462 1,901/13,457 7,773/54,176 0.0785†
(13.8) (14.1) (14.3)
10,675/14,560 11,030/14,645 44,261/58,465 0.0001†
(73.3) (75.3) (75.7)
9,370/14,560 9,138/14,645 38,368/58,465 0.0001†
(64.4) (62.4) (65.6)
9,928/14,560 9,197/14,645 41,507/58,465 0.0001†
(68.2) (62.8) (71.0)
10,620/14,127 9,871/14,051 43,710/56,657 0.0001†
(75.2) (70.3) (77.1)
17.0 [25.0] 38.0 17.0 [26.0] 40.0 17.0 [25.0] 38.0 0.0001*
1.0 [1.3] 1.8 1.0 [1.3] 1.8 1.0 [1.3] 1.8 0.0001*
21.0 [141.0] 162.0 118.0 [138.0] 160.0 122.0 [143.0] 166.0 0.0001*
73.0 [913.0] 1,778.5 416.0 [799.0] 1,630.0 453.0 [861.0] 1,700.00.0001*
0.7 [1.1] 2.0 0.6 [1.3] 3.9 0.5 [0.9] 1.8
3.2 (11.0) 6.8 (23.2) 4.8 (14.6) 0.0001‡
4.2 [5.5] 7.3 4.2 [6.0] 8.4 3.6 [5.0] 7.0 0.0001‡
3,503/14,560 4,180/14,645 17,376/58,465 0.0001†
(24.1) (28.5) (29.7)
2.6 [3.9] 6.5 2.8 [4.5] 7.1 2.6 [4.0] 6.7 0.0001‡
1.3 [2.5] 4.5 1.4 [2.8] 4.8 1.3 [2.3] 4.2 0.0001‡
453/14,560 583/14,645 2,041/58,465 0.0002†
(3.1) (4.0) (3.5)ith In
Treat
Qua
0 1
8.0 4riables, or ‡Wilcoxon test.
B-type natriuretic peptide; ICU  intensive care unit.
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August 12, 2008:534–40 BNP and Treatment Timehere were no differences in time to treatment with respect
o gender. In multivariate analysis, patients with a history of
hronic obstructive pulmonary disease or previous heart
ailure, and those with rales, congestion on chest X-ray, or
yspnea at rest received therapy earlier. On average, 79% of
atients in the first quartile of time to treatment had rales,
ompared with 63% for the fourth quartile (p 0.001). The
ercent of patients with rales also increased with increasing
NP quartiles from an average of 67% for iBNP 449
g/ml to 74% for the group with BNP levels 1,738 pg/ml
p  0.001). The presence of rales on initial examination
as associated with early recognition of heart failure and,
ence, earlier institution of therapy.
Interestingly, greater iBNP levels and rales on initial
xamination were closely associated. The multivariate data
emonstrated treatment delays in African Americans and
light delays in older patients. There were 23% of patients
ho had iBNP levels obtained 2 or more hours after
resentation. On multivariate analysis, treatment in an
cademic hospital, western and northeastern region, and
istory of stroke were associated with longer time to iBNP
easurement (Table 2).
Figure 1 shows the relationship of the time iBNP level was
rawn and time to treatment. Patients with the longest time to
BNP draw also had the longest time to treatment. This
elationship between time to treatment and time to iBNP level
as maintained throughout each quartile of BNP level (Fig. 2).
Figure 3 shows the average time spent in the ED by the
atient in hours by quartiles of time to treatment and iBNP
evel. Mean ED time increased with increased time-to-
reatment quartiles. Once again, this relationship was main-
ained throughout all quartiles of iBNP.
Figure 4 demonstrates the downstream effects of delayed
reatment of ADHF. The later the treatment took place, the
ospital and Patient Characteristicsred ctive of Delays in iBNP Testing
Table 2 Hospital and Patient CharacteristicsPredictive of Delays in iBNP Testing
Characteristic
Adjusted
Odds Ratio
95% Confidence
Intervals
Academic 1.453 1.370–1.540
Region
West vs. Mid-Atlantic 1.226 1.099–1.367
South vs. Mid-Atlantic 0.987 0.913–1.067
Northeast vs. Mid-Atlantic 1.877 1.679–2.099
Midwest vs. Mid-Atlantic 0.613 0.566–0.665
Previous heart failure history 0.869 0.814–0.927
Stroke 1.078 1.003–1.159
COPD 0.938 0.884–0.997
Beta-blocker use before admission 0.887 0.838–0.939
Dyspnea at rest 0.761 0.718–0.808
Congestion on examination 0.832 0.780–0.887
Rales 0.841 0.780–0.893
Pulse 0.999 0.997–1.000
Diastolic blood pressure 0.995 0.993–0.996
QRS duration on ECG 0.999 0.998–0.999OPD  chronic obstructive pulmonary disease; ECG  electrocardiogram; iBNP  immunoreac-
ive B-type natriuretic peptide.ewer proportion of patients were asymptomatic at the time
f discharge. Of note, within each quartile of treatment
ime, the greater the BNP level, the lower percentage of
atients who were asymptomatic at discharge.
Figure 5 shows unadjusted in hospital mortality data for
ach of the 16 time-to-treatment and iBNP subgroups.
ithin most time-to-treatment quartiles, mortality in-
reases with increasing iBNP. However, patients with low
BNP who received very early treatment constitute an
xception in that they experienced relatively greater mortal-
ty. This observation probably has a complex multifactorial
xplanation, as discussed herein. Within the 2 lower iBNP
uartiles, the mortality rate is essentially unchanged be-
ween the 1.05- and 4.98-h time-to-treatment groups.
owever, in the third-highest and the highest quartiles of
BNP, treatment delays associated with average increased
ortality from 3.7% to 4.1% and from 5.5% to 7.3%,
Figure 1 Time to iBNP Versus Time to Treatment
The relationship between median time to iBNP drawn by quartiles and median
time to initial intravenous diuretic treatment is shown. iBNP  immunoreactive
B-type natriuretic peptide; IV  intravenous.
Figure 2 Time to iBNP Versus Time
to Treatment by iBNP Quartile
The plot shows the relationship between mean time to iBNP level being drawn
and time to initial intravenous diuretic treatment for patients in each iBNP
quartile. iBNP  immunoreactive B-type natriuretic peptide; IV  intravenous.
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BNP and Treatment Time August 12, 2008:534–40espectively, which represents a relative increase in mortality
f 11% and 32%. After multivariable analysis, the increased
ortality in the highest iBNP quartile with treatment delays
emained statistically significant.
On multivariable GEE modeling accounting for the corre-
ation of data within hospitals, longer time to BNP as a
ontinuous variable was a modest predictor of increased in-
ospital mortality, independent of other predictive variables,
ith odds ratio (OR) (per hour) 1.004, 95% confidence
ntervals (CI): 1.002 to 1.006, and p 0.0002. Longer time to
V diuretic treatment was also independently associated with a
odest increased risk of in-hospital mortality in the GEE
odel with OR (per hour) 1.004, 95% CI 1.002 to 1.006, and
 0.0001. The risk-adjusted OR was 1.021, 95% CI: 1.010
o 1.033, and p 0.0001, per every 4-h delay. Other predictive
ariables are shown in Table 3.
Figure 3 ED Time Versus Quartiles
of Time to Diuretic by iBNP levels
The relationship between time to initial diuretic treatment and total time spent
in the emergency department (ED), divided into quartiles, is shown. Each quar-
tile of time to treatment is divided by quartiles of iBNP levels. iBNP  immuno-
reactive B-type natriuretic peptide; IV  intravenous.
Figure 4 Patients Asymptomatic at
Discharge Versus iBNP Levels
The influence of time to initial treatment on the percentage of patients who are
asymptomatic at hospital discharge is shown with time to initial diuretic treat-
ment divided into quartiles. Each quartile of time to treatment is divided by
quartiles of iBNP levels. iBNP  immunoreactive B-type natriuretic peptide;
IV  intravenous.miscussion
revious studies have shown that NP levels in patients pre-
enting with HF are predictive of future outcomes (9–14). In
oth acute and chronic HF, BNP provides important prog-
ostic information, with every 100 pg/ml increase associated
ith a 35% increase in the risk of death (15). Our data
emonstrate that in patients presenting to the ED with
DHF: 1) a delay in obtaining iBNP levels is associated with
rolonged time to treatment; 2) patients with rales on initial
xamination, and those with a history of coronary artery disease
r HF tend to receive earlier treatment; and 3) across a
pectrum of time-to-treatment and iBNP levels, both delayed
reatment and increased iBNP were modestly associated with
ncreased mortality. These observations remained valid
hether the data were analyzed by quartiles or as continuous
ariables and were independent of other prognostic variables,
uggesting that, with every successive delay there may be an
ncreased risk of adverse outcomes.
The data presented suggest that the diagnosis of ADHF
as often not made with sufficient certainty to initiate
reatment until after the iBNP level was known. Supporting
vidence for this hypothesis includes the paucity of physical
xamination findings, such as rales and edema, the absence
f congestion on the chest X-ray, and the absence of a
istory of HF in the patients who were treated later. The
ndings of this study suggest that substantial time delay
efore the iBNP level is obtained in the ED may contribute
o delay in initiating ADHF treatment with IV diuretics.
educing the time from arrival to iBNP blood draw may be
ppropriate for quality of care improvement efforts.
Several previous investigations have suggested that treat-
Figure 5 Hospital Mortality, Time
to Treatment, and iBNP Level
This 3-dimensional plot shows the relationship of hospital mortality (%) to time
of initial treatment (quartiles) and initial iBNP levels being drawn (quartiles).
iBNP  immunoreactive B-type natriuretic peptide; IV  intravenous.ent delays in ADHF are associated with worse outcomes.
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August 12, 2008:534–40 BNP and Treatment Timen a study of 8,000 patients transferred to hospital by
mbulance, of which 499 were ultimately diagnosed with
DHF, there was a significant reduction in mortality in
hose receiving early ADHF therapy compared with those
hose therapy was delayed by only 35 min (OR: 2.51, 95%
I: 1.37 to 4.55) (4). Although a mortality benefit was
bserved in the ADHF cohort, this was at the cost of a
arkedly increased death rate in the non-ADHF cohort if
istakenly diagnosed and treated for ADHF. In the 106
yspneic patients ultimately found to not have ADHF,
ortality was increased by 300% (from 3.8% to 13.8%,
 0.05) if they received ADHF therapy rather than
ppropriate treatment. A similar adverse effect of early but
nappropriate therapy may be a factor in explaining the high
ortality of our earliest treatment/lowest iBNP subgroup.
In an separate ADHERE registry analysis of patients
eceiving vasoactive infusions (defined as dopamine, dobut-
mine, milrinone, nesiritide, nitroglycerin, or nitroprusside)
or ADHF in the ED, compared with those receiving a
asoactive on the inpatient floor, an association of treatment
elay and adverse outcomes was reported (2,3). Patients
eceiving ED vasoactive agents had a significantly decreased
verall length of hospital stay (4.5 vs. 7 days, p  0.0001),
ntensive care unit (ICU) length of stay (2.0 vs. 3.1 days,
 0.0001), and in-hospital mortality (4.3% vs. 10.9%, p
.0001). Time-to-BNP levels and absolute BNP values
ere not recorded in this study.
Results congruent with the aforementioned analyses were
eported in another ADHERE registry evaluation of pa-
ients treated with nesiritide (16). This study compared
atients receiving ED nesiritide to those in whom therapy
as delayed until inpatient hospitalization. Early treatment
atients had a shorter mean length of hospital stay (5.4 vs.
.9 days) and, if treated in an ICU, they had shorter ICU
ength of stay (3.2 vs. 3.7 days). Patients who received
esiritide in the ED also had a fewer prolonged hospital-
zations, defined as 7 days (adjusted OR: 0.516, 95% CI:
.444 to 0.599), fewer ICU transfers (adjusted OR: 0.301,
5% CI: 0.206 to 0.440), and a significantly greater chance
f being discharged to home (adjusted OR: 1.154, 95% CI:
Variables Predictive of In-Hospital Mortality
Table 3 Variables Predictive of In-Hospital M
Variable Adjusted Od
Time to IV diuretic (per h) 1.00
Creatinine (per mg/dl) 1.04
BUN (per mg/dl) 1.01
Systolic blood pressure (per mm Hg) 0.98
Diastolic blood pressure (per mm Hg) 0.99
Serum sodium (per mEq/l) 0.97
Pulse (per beats/min) 1.01
Dyspnea at rest 1.50
Age (per yr) 1.03
BUN  blood urea nitrogen; IV  intravenous..005 to 1.325). (These consistent data support the hypothesis that the
bserved outcome differences result from the effect of
ime-to-treatment rather than the results of any specific
herapy. They may also explain the association between
elayed iBNP levels and delayed treatment. Because there is
penalty for delayed therapy as well as a penalty for
rroneous therapy, a treatment delay until iBNP diagnostic
onfirmation may not be unreasonable, as long as iBNP data
re available very soon after presentation. In the present
tudy, the longer it took for treatment, the worse the
rognosis. This is true except for the first quartile, where
atients were likely much sicker and therefore recognized as
F and treated earlier.
In unadjusted analysis, within each quartile of time to
iuretic, greater BNP levels were associated with a poorer
rognosis. The strength of this association decreased with
djustment for variables such as blood pressure and renal
unction, but both BNP and time to diuretic remained
ndependent predictors of mortality. Previous data from the
DHERE registry database have shown that initial iBNP
evels are highly predictive of in-hospital mortality for both
ystolic dysfunction and HF with preserved function (9,17).
hat study used a larger database that included all hospi-
alized HF patients. In this study, we looked at only patients
ho presented to an ED, had a timed BNP draw, and had
time notation as to when the first intravenous diuretic was
iven.
Time-to-treatment was associated with subsequent
ownstream outcomes. Patients who received prompt treat-
ent had shorter ED stays and a greater likelihood of being
symptomatic at subsequent hospital discharge. In contrast,
cross time-to-treatment quartiles, delayed therapy had the
ost notable adverse impact in those with the greatest
BNP levels.
oward improving the “door-to-diuretic time.” Because
apid assays for iBNP are widely available, we believe that
outinely obtaining iBNP data as part of the initial evalua-
ion of dyspneic patients would likely shorten time-to-
reatment and may improve outcomes. Data from both the
ASEL (B-type natriuretic peptide for Acute Shortness of
reath EvaLuation) study (18) and the IMPROVE CHF
lity
tio 95% Confidence Intervals p Values
1.002–1.005 0.0001
0.996–1.090 0.0743
1.017–1.022 0.0001
0.985–0.989 0.0001
0.987–0.994 0.0001
0.963–0.980 0.0001
1.013–1.017 0.0001
1.376–1.655 0.0001
1.033–1.042 0.0001orta
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BNP and Treatment Time August 12, 2008:534–40anagement of Patients with Suspected Acute Decompen-
ated Heart Failure) study (19) suggest that algorithms that
nclude NP testing from the point of ED entrance to hospital
ischarge shorten ED and hospital stay, reduce costs, and
educe 60-day rehospitalization rates.
tudy limitations. Potential limitations of the current
nalysis must be acknowledged. Because the ADHERE
egistry does not contain specific patient identifiers, the
ohorts analyzed may contain multiple distinct admissions
or the same patient. However, this issue should not have
nfluenced the study results; the principle outcome param-
ters, timing of treatment and in-hospital mortality as it
elates to the timing and level of admission iBNP, are
pecific to individual hospitalization episodes.
Also, because of the lack of patient identifiers, information
egarding patient status after hospital discharge is not available.
ifferences in disease assessment, background medical therapy
or HF, ED treatments, and documentation patterns at par-
icipating institutions could have influenced our findings. The
ime to iBNP and time to IV diuretic treatment may be proxies
or the overall quality of ED care. These differences in overall
D performance may help to account for the differences in
n-hospital mortality observed.
These data may not apply to patients who are cared for in
ettings that differ substantially from those institutions in
he ADHERE registry. Each patient’s actual timing of
reatment and risk for in-hospital mortality may be influ-
nced by many factors not measured or considered in this
nalysis. This study used results of various commercially
vailable BNP assays rather than results from a single central
ore laboratory. Although this methodology may introduce
reat variability to iBNP testing results, this approach
akes these findings more applicable to clinical practice.
onclusions
hese data from the ADHERE registry demonstrate that
elayed measurement of iBNP levels is strongly associated
ith delay in treatment for ADHF. Delays in ED treatment
or ADHF were modestly associated with increased mor-
ality during hospitalization, independent of other prognos-
ic variables. This effect occurred across a wide spectrum of
nitial iBNP levels but was most notable in patients with
reater iBNP levels, suggesting that the impact of treatment
elay may be amplified in more severely ill patients. Inter-
reting our findings in the context of previous studies,
rompt measurement of iBNP levels should be considered
s part of the immediate initial evaluation in patients with
uspected ADHF in the ED setting.
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an Diego VA Medical Center, 3340 La Jolla Village Drive,
an Diego, California 92161. E-mail: amaisel@ucsd.edu. K
rEFERENCES
1. American Heart Association. Heart Disease and Stroke Statistics:
2005 Update. Dallas, TX: American Heart Association, 2005.
2. Peacock WF, Emerman CL, Costanzo MR, Borkowitz RL, Cheng
M. Early initiation of intravenous therapy improves heart failure
outcomes: An Analysis from the ADHERE Registry Database. Ann
Emerg Med 2003;42:S26.
3. Peacock WF, Emerman CL, Costanza MR, Diercks DB, Lopatin M,
Fonarow G. Acute heart failure mortality is dependent on time to intravenous
vasoactive administration. J Cardiac Fail 2006;12 Suppl 1:S117.
4. Wuerz RC, Meador SA. Effects of prehospital medications on
mortality and length of stay in congestive heart failure. Ann Emerg
Med 1992;21:669–74.
5. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement
of B-type natriuretic peptide in the emergency diagnosis of heart
failure. N Engl J Med 2002;347:161–7.
6. Januzzi JL Jr., Camargo CA, Anwaruddin S, et al. The N-terminal
Pro-BNP investigation of dyspnea in the emergency department
(PRIDE) study. Am J Cardiol 2005;95:948–54.
7. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and
outcomes of patients hospitalized for heart failure in the United States
(2001–2003): rationale, design and preliminary observations from the
Acute Decompensated Heart Failure National Registry (ADHERE).
Am Heart J 2005;49:209–16.
8. Fonarow GC, Adams KF Jr., Abraham WT, Yancy CW, Boscardin WJ.
Risk stratification for in-hospital mortality in acutely decompensated heart
failure: classification and regression tree analysis. JAMA 2005;293:572–80.
9. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW;
ADHERE Scientific Advisory Committee and Investigators. Admis-
sion B-type natriuretic peptide levels and in-hospital mortality in acute
decompensated heart failure. J Am Coll Cardiol 2007;49:1943–50.
0. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid
Emergency Department Heart Failure Outpatient Trial (REDHOT).
A multicenter study of B-type natriuretic peptide levels, emergency
department decision making, and outcomes in patients presenting with
shortness of breath. J Am Coll Cardiol 2004;44:1328–33.
1. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic
peptide predicts future cardiac events in patients presenting to the
emergency department with dyspnea. Ann Emerg Med 2002;39:131–8.
2. O’Brien RJ, Squire IB, Demme B, Davies JE, Ng LL. Pre-discharge,
but not admission, levels of NT-proBNP predict adverse prognosis
following acute LVF. Eur J Heart Fail 2003;5:499–506.
3. Januzzi JL Jr., Sakhuja R, O’Donoghue M, et al. Utility of aminoter-
minal pro-brain natriuretic peptide testing for prediction of 1-year
mortality in patients with dyspnea treated in the emergency depart-
ment. Arch Intern Med 2006;166:315–20.
4. Januzzi JL Jr., Van Kimmenade RR, Lainchbury R, et al. NT-proBNP
testing for diagnosis and short-term prognosis in acute destabilized heart
failure: an international pooled analysis of 1256 patients: the International
Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330–7.
5. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type
natriuretic peptide predict death and cardiac events in patients with
heart failure: systematic review. BMJ 2005;330:625.
6. Peacock WF, Fonarow GC, Emerman CL, Mills RM, Wynne J. Impact
of early initiation of intravenous therapy for acute decompensated heart
failure on outcomes in ADHERE. Cardiology 2006;107:44–51.
7. Yancy CW, Lopatin M, Stevenson LW, de Marco T, Fonarow GC.
Clinical presentation, management, and in-hospital outcomes of
patients admitted with acute decompensated heart failure with pre-
served systolic function: a report from the Acute Decompensated
Heart Failure National Registry (ADHERE) Database. J Am Coll
Cardiol 2006;47:76–84.
8. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic
peptide in the evaluation and management of acute dyspnea. N Engl
J Med 2004;350:647–54.
9. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type
natriuretic peptide testing improves the management of patients with
suspected acute heart failure: primary results of the Canadian prospective
randomized multicenter IMPROVE-CHF study. Circulation 2007;115:
3103–10.ey Words: B-type natriuretic peptide y heart failure y mortality y
egistries y diuretics.
